Charles Lin - Kronos Bio Senior Development
| KRON Stock | USD 0.89 0.01 1.11% |
Executive
Charles Lin is Senior Development of Kronos Bio
| Age | 39 |
| Address | 1300 South El Camino Real, San Mateo, CA, United States, 94402 |
| Phone | (650) 781-5200 |
| Web | https://www.kronosbio.com |
Charles Lin Latest Insider Activity
Tracking and analyzing the buying and selling activities of Charles Lin against Kronos Bio stock is an integral part of due diligence when investing in Kronos Bio. Charles Lin insider activity provides valuable insight into whether Kronos Bio is net buyers or sellers over its current business cycle. Note, Kronos Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kronos Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Charles Lin over a month ago Acquisition by Charles Lin of 72900 shares of Kronos Bio at 0.96 subject to Rule 16b-3 |
Kronos Bio Management Efficiency
The company has return on total asset (ROA) of (0.2828) % which means that it has lost $0.2828 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.63) %, meaning that it created substantial loss on money invested by shareholders. Kronos Bio's management efficiency ratios could be used to measure how well Kronos Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.55. In addition to that, Return On Capital Employed is likely to drop to -0.68. At this time, Kronos Bio's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 42.7 M, while Net Tangible Assets are likely to drop about 225.4 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Richard Colonno | Assembly Biosciences | 74 | |
| Sara Besten | Generation Bio Co | N/A | |
| Isabel Chiu | C4 Therapeutics | N/A | |
| Anuj MD | Assembly Biosciences | 46 | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Dawn Benson | CytomX Therapeutics | N/A | |
| Robert Richard | Lyra Therapeutics | 66 | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Paul Bullock | Replimune Group | N/A | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Robert MD | Lyra Therapeutics | N/A | |
| MS CPA | Erasca Inc | 57 | |
| Christopher Sarchi | Replimune Group | 55 | |
| Andrew MD | Merus BV | 58 | |
| Jolie JD | C4 Therapeutics | 47 | |
| Tariq Ahmed | Achilles Therapeutics PLC | N/A | |
| Matt Cravets | Gossamer Bio | N/A | |
| Edward Samuel | Achilles Therapeutics PLC | N/A | |
| MBA MD | Replimune Group | 58 | |
| Jeanette Bjorkquist | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.28 |
Kronos Bio Leadership Team
Elected by the shareholders, the Kronos Bio's board of directors comprises two types of representatives: Kronos Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kronos. The board's role is to monitor Kronos Bio's management team and ensure that shareholders' interests are well served. Kronos Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kronos Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Dinsmore, Strategic Advisor | ||
| Stephanie Yao, Exec Communications | ||
| Barbara JD, Strategic Advisor | ||
| Marni Kottle, Sr Relations | ||
| Rocio Hoyos, Senior Management | ||
| Joshua Kazam, CoFounder Director | ||
| Sandra Gardiner, Interim Officer | ||
| MPH DO, Senior Development | ||
| Norbert Bischofberger, CEO President | ||
| Allison JD, Senior Counsel | ||
| Charles Lin, Senior Development | ||
| Deborah Knobelman, COO CFO | ||
| BCh BM, CFO Devel | ||
| David JD, Secretary Director | ||
| Margaux Bennett, Vice Relations | ||
| Wes Trotter, Senior Development |
Kronos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kronos Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.49) % | ||||
| Current Valuation | (44.57 M) | ||||
| Shares Outstanding | 60.34 M | ||||
| Shares Owned By Insiders | 26.90 % | ||||
| Shares Owned By Institutions | 32.67 % | ||||
| Number Of Shares Shorted | 527.68 K | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 6.48 X |
Pair Trading with Kronos Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Kronos Stock
| 0.7 | ME | 23Andme Holding | PairCorr |
| 0.7 | VALN | Valneva SE ADR | PairCorr |
| 0.69 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Kronos Stock
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.